Politics

Why are Democrats talking about scrapping some of the most popular parts of their agenda?

The biggest-spending lobbying organization in the country, the U.S. Chamber of Commerce, adamantly opposes Democrats’ ideas for drug pricing reform, saying they are unwelcome government price controls.

Rep. Scott Peters, a California Democrat, is drawing fire from liberal lawmakers and groups in the fight to lower prescription-drug costs.

Ten House Democrats fired a warning shot in the spring that they could cause trouble for House Speaker Nancy Pelosi’s signature drug pricing reform legislation.

A Senate leader crafting a drug pricing proposal is trying to win the support of moderate Democrats by promising to carve out exceptions for small biotech companies.

David Sirota breaks down progressives' path to victory on prescription drug pricing reform.

Democratic Senator Kyrsten Sinema has decided that she doesn't want Americans to have access to lower-cost prescription drugs, and her opposition to a bill that would do exactly that didn't come out of the blue.

Members of Congress want to ensure that reports from the national academies, chartered in 1863 to provide Congress with expert scientific advice, are widely accepted as independent and free from special-interest or financial influence.

Democrats can’t do much on health care if they don’t cut prescription drug costs.

Enbrel

The accelerated approval pathway is under fire as the agency recently signed off on a controversial new Alzheimer’s drug, with little precedent to explain its decision.

Democrats are counting on the drug policy proposal, which could generate budgetary savings of as much as $700 billion over a decade, to help pay for their other health policy priorities.

Drugs are inherently expensive to make. In 2016 a group from Tufts estimated that a new drug on average costs $2.6 billion (2013 dollars) to create, growing at 8.5% per year above general price inflation.

Among the targets: giving drug companies new protections for changes to old inventions.

A bill in Congress would allow Medicare to use its bulk-purchasing power to negotiate lower drug prices. Big Pharma is not pleased.